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The transmembrane protein neuropilin-1 (NRP1) promotes vascular endothelial growth factor (VEGF)
and extracellular matrix signaling in endothelial cells (ECs). Although it is established that NRP1 is
essential for angiogenesis, little is known about its role in EC homeostasis. Here, we report that
NRP1 promotes mitochondrial function in ECs by preventing iron accumulation and iron-induced
oxidative stress through a VEGF-independent mechanism in non-angiogenic ECs. Furthermore,
NRP1-deficient ECs have reduced growth and show the hallmarks of cellular senescence. We
show that a subcellular pool of NRP1 localizes in mitochondria and interacts with the mitochondrial
transporter ATP-binding cassette B8 (ABCB8). NRP1 loss reduces ABCB8 levels, resulting in iron accu-
mulation, iron-induced mitochondrial superoxide production, and iron-dependent EC senescence.
Treatment of NRP1-deficient ECs with themitochondria-targeted antioxidant compoundmitoTEMPO
or with the iron chelator deferoxamine restores mitochondrial activity, inhibits superoxide produc-
tion, and protects from cellular senescence. This finding identifies an unexpected role of NRP1 in
EC homeostasis.
INTRODUCTION
Neuropilin-1 (NRP1) is a transmembrane protein expressed by many cell types including endothelial cells
(ECs) (Raimondi et al., 2016). Ablation of NRP1 expression in mice results in embryonic lethality caused by
severe neural and vascular defects (Kawasaki et al., 1999; Kitsukawa et al., 1997). NRP1-dependent
signaling pathways in ECs are essential for vascular development because endothelial-specific NRP1
knockout mice recapitulate the vascular defects of the global NPR1 knockout (Gu et al., 2003). ECs line
the inner surface of blood vessels forming a quiescent selectively permeable monolayer and proliferate
rarely over months or years (Augustin, 2004). In contrast, ECs proliferate and migrate in response to pro-
angiogenic factors such as vascular endothelial growth factor (VEGF-A) during angiogenesis. NRP1 has
been mainly investigated as a co-receptor for VEGF-A, but recent evidence shows that NRP1 also regulates
VEGF-independent extracellular-matrix-mediated pathways that promote physiological and pathological
angiogenesis (Fantin et al., 2015; Raimondi et al., 2014, 2015). Although the role of NRP1 in angiogenesis is
well understood, the contribution of NRP1 signaling in the adult quiescent vasculature is less defined. The
maintenance of endothelial homeostatic function over time is critical to prevent excessive permeability,
thrombosis, and inflammation (Rajendran et al., 2013; Sena et al., 2013). In the adult vasculature, NRP1
has been implicated in VEGF-induced vascular permeability (Acevedo et al., 2008; Becker et al., 2005; Fan-
tin et al., 2017; Raimondi et al., 2016; Roth et al., 2016) and in vascular leakage in a mouse model of diabetic
retinal injury (Wang et al., 2015), but whether NRP1 has a broader role in EC homeostasis is poorly
understood.
Mitochondria are emerging as regulators of EC signaling and function. ECs rely mainly on anaerobic glycol-
ysis to meet their energy demand and to produce ATP (De Bock et al., 2013); thus mitochondrial contribu-
tion to EC energy production is limited in physiological conditions. However, mitochondria are essential for
EC function because altering mitochondrial dynamics induces endothelial dysfunction (Shenouda et al.,
2011). Accordingly, mitochondria regulate shear stress-induced vasodilation, hypoxia signaling, auto-
phagy, and pro-inflammatory activation by producing mitochondrial reactive oxygen species (ROS), which
act as a signaling molecule (Al-Mehdi et al., 2012; Liu et al., 2008). Conversely, fragmentation of the mito-
chondrial network occurs in ECs following exposure to oxidative stress (Jendrach et al., 2008), high glucoseiScience 11, 205–223, January 25, 2019 ª 2018 The Author(s).
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(Shenouda et al., 2011), and ischemia-reperfusion injury (Giedt et al., 2012; Makino et al., 2010). Although
this evidence suggests that mitochondrial homeostasis and EC function are deeply entwined, the mecha-
nism that regulates mitochondrial function in ECs is not completely understood.
Mitochondria are also a focal point for the regulation of cellular redox potential and iron metabolism. Mito-
chondria synthesize the iron-sulfur protein (Fe/S) clusters, which are essential for the electron transfer re-
actions and produce the heme’s precursor compound protoporphyrin IX (Beinert et al., 1997; Hamza
and Dailey, 2012; Lill et al., 1999). Thus mitochondria require iron to function and play a central role
in iron metabolism. Defects in mitochondria biogenesis and morphology contribute to endothelial
dysfunction and to the pathogenesis of cardiovascular diseases (Ong et al., 2010; Shenouda et al., 2011).
Accordingly, the extent of atherosclerosis correlates with mitochondrial DNA damage in patients and in
atherosclerosis mouse models (Ballinger et al., 2002). Furthermore, depletion of mitochondrial biogenesis
regulator peroxisome proliferator-activated receptor g coactivator 1a results in vascular dysfunction and
inflammation because of increased mitochondrial ROS production in response to chronic angiotensin II
infusion (Kroller-Schon et al., 2013).
ROS are mainly generated as a by-product of the mitochondria electron transport chain during oxidative
phosphorylation (Turrens, 2003) or by accumulation of transition metals such as iron. Accumulation of ionic
iron induces the formation of redox-active iron pools able to catalyze the production of free radical via
Fenton chemistry (Kell, 2009; Silva-Gomes et al., 2014). ECs are equipped to withstand mechanical and
chemical stresses and to maintain their function despite the physiological increases of cytokines, chemo-
kines, and ROS during inflammation or infection. However, recent evidence shows that prolonged sus-
tained ROS levels contribute to endothelial dysfunction and to the inflammatory response in atheroscle-
rosis and coronary heart diseases (Cai and Harrison, 2000; Forstermann, 2008; Panth et al., 2016).
Furthermore, elevated ROS levels induce premature EC senescence, which impairs EC function and
homeostasis. In the aging cardiovasculature, senescent ECs accumulate in atherosclerotic lesions and
likely contribute to disease progression by creating a pro-inflammatory and pro-thrombotic environment
(Minamino et al., 2002; Vasile et al., 2001; Warboys et al., 2014).
Senescent cells irreversibly lose the ability to replicate and thereby contribute to tissue aging by disrupting
tissue homeostasis (van Deursen, 2014). Replicative cell senescence is usually caused by progressive telo-
mere shortening at each round of cell duplication (Cristofalo et al., 2004; Shay and Wright, 2005). In addi-
tion, DNA damage, oxidative stress, or mitochondrial dysfunction can cause premature senescence by
telomere-independent mechanisms (Erusalimsky, 2009). EC senescence impairs vascular functions such
as angiogenesis, nutrient trafficking, and vascular repair because it decreases proliferation and migration
of ECs (Foreman and Tang, 2003).
Here, we found that in addition to the well-established role in angiogenesis, NRP1 also has a role in EC
health in non-angiogenic conditions by promoting mitochondrial function through the mitochondria-spe-
cific ATP-binding cassette transporter ABCB8 (Ichikawa et al., 2012, 2014). Downregulation of NRP1
increases iron levels in ECs and induces iron-dependent oxidative stress, which results in mitochondrial
superoxide production, decreased mitochondrial activity, and EC senescence. As iron chelation restored
mitochondrial activity, reduced mitochondrial superoxide, and reduced EC senescence in NRP1-deficient
ECs, our findings indicate that NRP1 protects ECs frommitochondrial damage by reducing iron-dependent
oxidative stress and thereby decreases premature EC senescence.RESULTS
NRP1 Localizes in the Mitochondria and Controls Mitochondrial Morphology in ECs
Independently of VEGFR2
To investigate a potential role of NRP1 in mitochondria, we first investigated whether NRP1 localizes in the
mitochondria of humanmicrovascular endothelial cells (HDMECs) by performing immunostaining for NRP1
and the mitochondrial outer membrane component TOM20. Specificity of anti-NRP1 antibody was
confirmed by staining HDMECs downregulated for NRP1 expression using a previously validated small
interfering RNA (siRNA) (Fantin et al., 2015, 2017; Raimondi et al., 2014) (Figures S1A and S1B). As expected,
NRP1 was distributed throughout the cytoplasm and was enriched at the plasma membrane and in
filopodia (Figure S1A). Co-localization analysis of de-convoluted high-magnification z stack, which gener-
ated pseudo-colored ‘‘product of the differences from themean’’ (PDM) images in which each pixel is equal206 iScience 11, 205–223, January 25, 2019
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Figure 1. NRP1 Localizes in the Mitochondria and Regulates Mitochondrial Dynamics
(A) HDMECs were stained for NRP1 (green) and TOM20 (red). Deconvoluted images of optical z stacks to visualize NRP1
and TOM20 co-localization; pseudo-colored ‘‘product of the differences from the mean’’ (PDM) images in which each
pixel is equal to the PDM value are shown with a PDM scale; scale bar, 15 mm.
(B) Mitochondrial and cytoplasmic fractions of HDMECs lysates were probed for NRP1, GAPDH, ABCB8, and TOM20.
Immunoblotting representative of n = 4 experiments.
(C) Representative immunoblot for NRP1 and VEGFR2 in HDMECs transfected with si-NRP1, si-VEGFR2, or si-control for
72 hr; n = 3.
(D) Quantification of NRP1 and VEGFR2 mRNA by RT-qPCR in HDMECs transfected for 72 hr with si-NRP1, si-VEGFR2, or
si-control. NRP1 and VEGFR2 levels were expressed as fold change of si-control (mean G SEM; n = 3).
(E) HDMECs transfected with the indicated si-RNAs were stained for mitochondria using MitoTracker (red) and
counterstained with DAPI; scale bars, 15 mm.
(F) Quantification of mitochondrial network in optical z stacks after applying amask to quantify MitoTracker-positive areas
and volumes (mean G SEM; n = 3).
(G) Immunoblotting for NRP1 and TOM20 in HDMECs transfected with si-NRP1 or si-control for 72 hr with GAPDH used as
control.
(H) TOM20 levels in immunoblots were quantified as pixel intensity relative to GAPDH, and values expressed as fold
change of si-control (mean G SEM; n = 3).
(I) Immunoblotting for NRP1, MFN1, and MFN2 in HDMECs transfected with si-NRP1 or si-control for 72 hr with GAPDH
used as control.
(J) MFN1 levels in immunoblots were quantified as pixel intensity relative to GAPDH, and values expressed as fold change
of si-control (mean G SEM; n = 3).
*p < 0.05, **p < 0.01, ***p < 0.001; n.s., not significant; Student’s t test. See also Figure S1.to the PDM value, showed that NRP1 co-localizes with TOM20 in the mitochondria (Figures 1A, S1C, S1C0,
and S1D). We further investigated whether NRP1 is in close proximity with TOM20 by performing proximity
ligation assay (PLA), which generates a fluorescent signal when target proteins are within a distance of
40 nm. Interestingly, HDMEC si-control showed a positive PLA signal, which was significantly decreased
in HDMEC si-NRP1 (Figures S1E and S1F), suggesting that NRP1 localizes in the mitochondria. To confirm
this finding, we performed mitochondrial fractionation. Cytoplasmic and mitochondrial fractions of
HDMECs were immunoblotted for the cytoplasmic marker GAPDH and for the mitochondrial inner and
outer membranesmarkers ABCB8 and TOM20, respectively (Figure 1B). Furthermore, fractions were immu-
noblotted for the endoplasmic reticulum (ER) marker KDEL and for the endosome marker EEA1 (Fig-
ure S1G). Importantly, the mitochondrial fraction was negative for cytoplasmic, endosomal, and ER
markers, indicating that the mitochondrial fractions isolated were pure. Strikingly, NRP1 was detected
by immunoblotting in the mitochondrial fraction (Figures 1B and S1G) as well as in the cytoplasmic fraction
and in the whole lysate. Together these data show that a subcellular pool of NRP1 localizes into the
mitochondria.
To determine whether NRP1 or VEGF signaling plays a role in mitochondrial function, we downregulated
NRP1 or VEGFR2 expression in HDMECs and investigated mitochondrial morphology. Thus we analyzed
the mitochondrial network coverage in HDMECs transfected with NRP1 targeting, VEGFR2-targeting, or
with control siRNA (Figures 1C and 1D). Mitochondria were live stained with MitoTracker, and mitochon-
drial network area and volume were quantified by generating a 3D-rendered surface built on the Mito-
Tracker fluorescence from optical z stacks acquired through high-resolution confocal microscopy (Fig-
ure 1E). Quantification revealed that NRP1-deficient, but not VEGFR2-deficient, HDMECs have reduced
mitochondrial area and volume compared with control cells, suggesting that NRP1 regulates the extent
of mitochondrial network independently of VEGF signaling (Figure 1F).
Then, we analyzed the protein level of the mitochondrial mass indicator TOM20 by immunoblotting, as a
measurement of mitochondrial content (Burbulla et al., 2014). In agreement with the reduced mitochon-
drial network coverage (Figures 1E and 1F), NRP1 downregulation in HDMECs significantly reduced
TOM20 levels compared with control cells, suggesting a decrease in mitochondrial mass in NRP1-deficient
HDMECs (Figures 1G and 1H).
Because mitochondria are organized in a network maintained by organelle fission and fusion (Chan, 2006),
we investigated whether NRP1 downregulation affects the expression of mitofusin-1 (MFN1) and
mitofusin-2 (MFN2), which are known to promote mitochondrial fusion (Lugus et al., 2011; Ong et al.,
2010). In agreement with the reducedmitochondrial network observed above (Figures 1E and 1F), we found208 iScience 11, 205–223, January 25, 2019
that NRP1 downregulation significantly decreases MFN1, but not MFN2 expression (Figures 1I and 1J).
Together, these data show that a pool of NRP1 localizes in the mitochondria and that NRP1 regulates mito-
chondrial mass and the organization of the mitochondrial network in ECs.NRP1 Protects Mitochondrial Activity and Prevents Oxidative Stress in ECs
Because NRP1 loss reduces mitochondrial mass and mitochondrial network coverage, we investigated
whether NRP1 promotes mitochondrial activity. In aerobic conditions, NADH and FADH2 produced during
glycolysis, b-oxidation, and other catabolic processes are oxidized using molecular oxygen by the electron
transport chain complexes. The transfer of electrons through the mitochondrial complexes I–IV located in
the inner mitochondrial membrane provides the energy to generate an H+ gradient across the inner mito-
chondrial membrane, which creates an inter-membrane mitochondrial potential (DJ) functional to ATP
production. Thus we measured DJ by live staining HDMECs transfected with si-NRP1, si-VEGFR2, or si-
control with the fluorescent dye tetramethylrhodamine methyl ester (TMRM), whose accumulation into
the mitochondria depends on DJ (Scaduto and Grotyohann, 1999). Accordingly, treatment of HDMECs
with the electron transport chain uncoupler carbonyl cyanidem-chlorophenylhydrazone completely abro-
gated TMRM mitochondrial accumulation (Figure S2A). Confocal analysis showed that NRP1 downregula-
tion, but not VEGFR2 knockdown, significantly reduced TMRM staining compared with si-control (Figures
2A and 2B). Together, these data demonstrate that NRP1 regulates mitochondrial membrane potential and
suggest that NRP1 promotes mitochondrial function in a VEGF-independent manner.
As NRP1 downregulation reduced the area and volume of the mitochondrial network (Figures 1E and 1F),
we investigated whether the decreased TMRM staining observed in ECs lacking NRP1 was due to a
reduced mitochondrial content or to a genuine reduction in the proton motive force. Thus we co-labeled
HDEMCs and human umbilical vein endothelial cells (HUVECs) with TMRM and MitoTracker to measure
simultaneously DJ and mitochondrial content. Strikingly, NRP1 downregulation reduced the TMRM/
MitoTracker ratio in HDMECs (Figures 2C and 2D) and HUVECs (Figures S2B and S2C). Furthermore,
downregulation of NRP1 in HDMECs with two different NRP1-targeted siRNAs (Figure S2D) confirmed
a reduction of TMRM/MitoTracker staining in cells lacking NRP1 expression (Figures S2E and S2F),
indicating that the mitochondrial phenotype observed is not due to siRNA off-target effects. Together,
these data indicate that lack of NRP1 expression in EC decreases mitochondrial proton motive force
independently of the reduction in mitochondrial content.
As oxidative damage reduces mitochondrial activity and disrupts the organization of the mitochondrial
network (Jendrach et al., 2008), we investigated whether NRP1 downregulation induces mitochondrial
ROS production. HDMECs expressing or lacking NRP1 were live stained with the mitochondria-specific
dye MitoSOX, which becomes fluorescent upon superoxide-mediated oxidation (Figure 2E). Strikingly,
HDMECs lacking NRP1 expression showed significantly higher mitochondrial ROS compared with control,
indicating that NRP1 expression suppresses mitochondrial ROS production (Figures 2E and 2F). Because
inhibition of the endogenous antioxidant cellular system could lead to increased ROS levels, we investi-
gated the role of NRP1 and VEGF signaling in the expression of the antioxidant enzymes superoxide dis-
mutase 1 (SOD1), SOD2, and NRF2 in HDMECs. Interestingly, NRP1 downregulation, but not VEGFR2
knockdown, significantly reduced SOD1 expression compared with control cells (Figure 2G), whereas
SOD2 and NRF2 expression was significantly reduced in cells transfected with either NRP1 or VEGFR2
siRNA (Figure 2G). Then, we investigated the expression of heme oxygenase 1 (HO-1), which is known to
protect against oxidative stress and whose expression is strongly induced by a wide array of pro-oxidant
and inflammatory stimuli (Luo et al., 2017). Downregulation of NRP1 induced a 10-fold upregulation of
HO-1 expression compared with si-control, whereas VEGFR2 knockdown had no effect on HO-1 expression
(Figure 2G). Accordingly, HO-1 protein level was significantly upregulated in HDMECs si-NRP1 (Figures
S2G and S2H). Taken together, these data suggest that NRP1- and VEGF-mediated signaling pathways
cooperate to maintain the cellular antioxidant defense system in HDMECs and that NRP1 loss induces
an oxidative stress response that leads to HO-1 upregulation in ECs.
To further study the role of NRP1 in oxidative stress, we investigated whether NRP1 loss induces oxidative
stress in vivo by measuring oxidative stress in the Tg(fli1a:EGFP)y5-labeled vasculature of nrp1asa1485/sa1485
mutant (nrp1a/-) zebrafish embryos. Live transgenic embryos at 3 days post-fertilization (dpf) were stained
with CellROX dye, which detects generalized oxidative stress (Mugoni et al., 2014). To measure ROS spe-
cifically in the vasculature, we quantified CellROX fluorescence in isolatedGFP-positive territories obtainediScience 11, 205–223, January 25, 2019 209
Figure 2. NRP1 Regulates Mitochondrial Activity and Suppresses Oxidative Stress
(A) HDMECs transfected with si-NRP1, si-VEGFR2, or si-control were incubated with 100 nM TMRM and DRAQ5 (blue) and live imaged with a confocal
microscope; scale bar, 20 mm.
(B) Integrated density of TMRM signal per cell was quantified and expressed as percentage (mean G SEM; n = 4) of si-control.
(C) HDEMCs transfected with siNRP1 or si-control were incubated with 100 nM TMRM and 300 nM MitoTracker Deep Red FM; scale bar, 20 mm.
(D) TMRM and MitoTracker Deep Red FM integrated density was calculated, and the TMRM/MitoTracker ratio visualized in the graph (meanG SEM; n = 4).
(E) HDMECs transfected with si-NRP1 or si-control were incubated with 5 mM MitoSOX (red and gray) and counterstained with Hoescht 33342 (blue); scale
bar, 20 mm.
(F) Integrated density of the MitoSOX signal per cell was quantified and expressed as percentage relative to si-control (mean G SEM; n = 3).
(G) Quantification of superoxide dismutase-1 and 2 (SOD1, SOD2), NRF2, and heme oxygenase-1 (HO-1) mRNA by RT-qPCR in HDMECs si-NRP1 or si-
control expressed as fold change of si-control (mean G SEM; n = 3).
(H) Tg(fli1a:egfp)y5 wild-type and nrp1asa1485 zebrafish embryos at 3 dpf were incubated with 2.5 mMCellROX (gray) in 10% DMSO for 45 min before imaging;
scale bars, 40 mm. (H0) Higher-magnification images of area indicated in the square box in H; white arrows indicate ECs in ISV with high CellROX staining.
(I) CellROX mean intensity was quantified in optical z stacks in nR 16 embryos from three independent experiments after applying a mask to quantify
CellROX-positive areas and volumes (mean G SEM) within the vasculature.
(J) HDMECs treated with mitoTEMPO 10 mM for 24 hr after 48 hr from transfection with si-NRP1 or si-control were incubated with 100 nM TMRM (gray); scale
bar, 20 mm.
(K) Integrated density of the TMRM signal per cell was quantified and normalized to cell number determined by manual counting using high-contrast images
(panel J, green images) and expressed as percentage relative to si-control (mean G SEM; n = 3).
*p < 0.05, ***p < 0.001; Student’s t test. See also Figure S2).
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by applying a virtual mask to the z stacks acquired by high-resolution confocal microscopy. Quantification
of CellROX in the masked GFP-positive 3D projections showed that Tg(fli1a:EGFP)y5nrp1a/- embryos had
significantly higher CellROX signal within the vasculature compared with control embryos (Figures 2H
and 2I). Furthermore, ECs in the intersomitic vessels (ISV) of nrp1a/- knockout embryos were highly pos-
itive for CellROX (white arrows, Figure 2H0), suggesting that the migratory ECs forming the ISVs are likely
more susceptible to oxidative stress upon NRP1 deletion. These data demonstrate that NRP1 reduces
oxidative stress in vivo and prompted us to investigate the molecular mechanism by which NRP1 regulates
the redox status in ECs.
Because NRP1 downregulation reducesmitochondrial activity (Figures 2A–2D) and induces oxidative stress
(Figures 2F–2I), we hypothesized that the increased oxidative stress observed in NRP1-deficient ECs dam-
ages the mitochondria and results in reduced mitochondrial activity. Thus, we measured DJ in HDMECs
expressing or lacking NRP1 and treated with the mitochondria-targeted antioxidant mitoTEMPO
(Figure 2J), which is known to preserve mitochondrial membrane potential in oxidative stress conditions
(Dikalova et al., 2010). Strikingly, mitoTEMPO treatment of HDMECs si-NRP1 significantly increased DJ
to a level similar to control (Figures 2J and 2K), indicating a recovered mitochondrial membrane potential
in NRP1-deficient HDMECs following the mitoTEMPO treatment. These data suggest that ROS induce
mitochondrial damage, which results in lowered mitochondrial activity in NRP1-deficient HDMECs.
To further investigate the role of NRP1 in the mitochondria of ECs, we used a mass-spectrometry-based
post-translation modification analysis (PTMscan) approach to analyze changes in serine phosphorylation
in the proteome of HDMECs transfected with si-NRP1 or si-control. We found that NRP1 downregulation
affected serine phosphorylation of several mitochondrial enzymes (Figure S2I, Table S1). Phosphorylation
of ATPase family AAA-domain-containing protein 1 and of the precursor of NADH dehydrogenase flavo-
protein 3 isoform b was affected. Furthermore, NRP1 knockdown reduced pyruvate dehydrogenase E1
component subunit alpha isoform 2 phosphorylation, which is known to inhibit pyruvate dehydrogenase
enzymatic activity (Akhmedov et al., 2012). Strikingly, the mitochondrial-specific ATP-binding cassette
(ABC) subfamily B member 8 (ABCB8) was 48 times less phosphorylated in HDMECs lacking NRP1
compared with si-control (Figure S2I, Table S1). The ATP-binding cassette transporter superfamily consists
of transmembrane proteins that translocate substrates such as peptides, inorganic anions, amino acids,
polysaccharides, proteins, vitamins, and metallic ions across extra- and intracellular membranes (Begicevic
and Falasca, 2017). Specifically, ABCB8 is a constituent of the inner mitochondrial membrane recently
shown to be involved in mitochondrial iron export (Dean and Allikmets, 2001; Ichikawa et al., 2012). These
data indicate that NRP1 modulates mitochondrial function by regulating phosphorylation of key mitochon-
drial proteins and strongly suggest that NRP1 could regulate mitochondrial iron transport via ABCB8.NRP1 Interacts with the ATP-Binding Cassette Protein ABCB8
Given that NRP1 loss reduces phosphorylation of ABCB8, we hypothesized that NRP1 regulates iron levels
and iron-induced oxidative stress via ABCB8 in ECs. We first confirmed that ABCB8 is expressed in
HDMECs and localizes in the mitochondria by co-staining HDMECs for ABCB8 and TOM20 (Figure S2J).
We then investigated ABCB8 serine phosphorylation in HDMECs si-NRP1 or si-control by PLA using an
anti-phosphoserine and an anti-ABCB8 antibody or control IgG (Figure 3A). In accordance with PTMscan
data, the PLA signal detected in HDMECs si-NRP1 was significantly reduced compared with HDMECs si-
control (Figure 3B). Because the changes in ABCB8 phosphorylation levels detected by PTMscan and
PLA in HDMECs lacking NRP1 could result from a reduction in ABCB8 expression, we investigated whether
NRP1 downregulation reduces ABCB8 transcript and protein levels. NRP1 downregulation had no effect on
ABCB8 mRNA level (Figure 3C), whereas ABCB8 protein levels were significantly reduced in HDMECs lack-
ing NRP1 compared with control (Figures 3D and 3E), indicating that the reduced levels of ABCB8 phos-
phorylation could be caused by a decrease in ABCB8 expression. To examine if NRP1 promotes ABCB8
protein expression in vivo, we analyzed ABCB8 protein levels in aortas of adult conditional Nrp1-null
mice lacking (Nrp1WT) or expressing a tamoxifen-inducible, endothelial-specific Cre transgene (Nrp1ECKO).
NRP1 and ABCB8 staining was performed on whole-mount aortas where ECs were counterstained with
PECAM (Figures 3F and S1H). Tamoxifen treatment significantly reduced NRP1 expression in ECs of
Nrp1ECKO compared with Nrp1WT control littermates, indicating that NRP1 was efficiently depleted. Strik-
ingly, ABCB8 expression was significantly reduced in the endothelium ofNrp1ECKO compared withNrp1WT
littermates (Figures 3F and 3G). Taken together, these data demonstrate that NRP1 regulates ABCB8 pro-
tein levels in vitro and in vivo.iScience 11, 205–223, January 25, 2019 211
Figure 3. NRP1 Localizes into the Mitochondria and Interacts with ABCB8
(A) PLA for ABCB8 and phosphoserine in HDMECs si-control or si-NRP1; PLA with IgG isotypes was performed as control; scale bar, 20 mm.
(B) PLA signal (gray) per cells (mean G SEM) was measured in a minimum of 177 cells from two independent experiments; # = number of cells analyzed.
(C) Quantification of ABCB8 mRNA by RT-qPCR in HDMECs si-NRP1 or si-control; n = 3.
(D) HDEMC si-NRP1 and si-control were stained for ABCB8 (green) and counterstained with DAPI (blue); scale bars, 20 mm.
(E) Integrated density of ABCB8 signal was quantified and expressed as percentage relative to si-control (mean G SEM; n = 3).
(F) Aortas of Nrp1fl/fl (Nrp1WT) or Nrp1fl/fl;Cdh5(PAC)-iCreERT2 (Nrp1ECKO) littermates injected daily with tamoxifen for 5 days and sacrificed after 1 month
from injections were immunostained for NRP1, ABCB8, and PECAM; scale bar, 30 mm.
(G) NRP1 and ABCB8 pixel number and intensity were measured in optical z stacks, normalized to DAPI, and expressed as percentage of Nrp1WT (meanG
SEM; nR 3 mice each genotype; **p < 0.005, ***p < 0.001, two-way ANOVA).
(H) Co-immunoprecipitation of endogenous NRP1 and ABCB8 protein from lysates of HDMECs performed with an anti-NRP1 antibody, followed by
immunoblotting for NRP1 and ABCB8 (n = 3).
(I) PLA for NRP1 and ABCB8 in HDMECs si-control or si-NRP1. PLA with IgG isotypes was performed as control; scale bar, 20mm.
(J) Average PLA signal (gray) per cells (mean G SEM) was measured in a minimum of 59 cells from four independent experiments.
# = number of cells analyzed; *p < 0.05; **p < 0.005, ***p < 0.001; n.s., not significant; Student’s t test. See also Figures S1 and S2.Because ABCB8 is a mitochondria-specific protein and a subcellular pool of NRP1 localizes in the mito-
chondria, we investigated whether NRP1 forms a protein complex with ABCB8 in HDMECs. Immunoprecip-
itation analysis performed by pulling down endogenous NRP1 and by probing the immunoprecipitated
fraction for NRP1 and ABCB8 showed that NRP1 and ABCB8 form a protein complex (Figure 3H). PLA212 iScience 11, 205–223, January 25, 2019
confirmed the protein-protein interaction observed by co-immunoprecipitation analysis (Figures 3I and 3J).
These data further demonstrate that NRP1 localizes in the mitochondria and show that NRP1 interacts with
ABCB8; the results also strongly suggest that the formation of this complex promotes ABCB8 function.
Furthermore, the data suggest that NRP1 suppresses mitochondrial iron accumulation via ABCB8, thus
preventing iron-dependent oxidative stress.
NRP1 Regulates Iron Homeostasis and Suppresses Iron-Dependent Oxidative Stress in ECs
To investigate whether NRP1 regulates iron homeostasis, we measured intracellular ferrous (Fe2+) and
ferric (Fe3+) content in HDMECs lacking or expressing NRP1 using a ferene S-based colorimetric assay
(Bai et al., 2017; Ichikawa et al., 2012). Intracellular iron was significantly higher in HDMECs downre-
gulated for NRP1 expression compared with control (Figure 4A), indicating that NRP1 loss results in
iron accumulation. To further investigate whether NRP1 downregulation induces mitochondrial iron
accumulation we measured Fe2+ in HDMECs expressing or lacking NRP1 expression by incubating
ECs with Mito-FerroGreen, a mitochondria-specific iron probe that becomes fluorescent when reacting
with labile mitochondrial Fe2+ (Hirayama et al., 2018). Co-staining of HDMECs with Mito-FerroGreen
and MitoTracker confirmed a complete mitochondrial localization of Mito-FerroGreen in HDMECs (Fig-
ure 4B). In agreement with the increased intracellular iron observed in HDMECs si-NRP1 (Figure 4A),
NRP1 downregulation induced a significant increase in mito-FerroGreen staining, indicating that loss
of NRP1 expression induces mitochondrial iron accumulation in ECs (Figures 4B and 4C).
Then we investigated the expression of iron transporters known to modulate intracellular iron levels. No
change was observed in the mRNA levels and protein expression of transferrin receptor 1, which mediates
cellular iron uptake (Figures S3A and S3B). Expression of ferroportin-1, which regulates EC iron efflux, was
significantly increased at the protein level (Figure 4D), but unchanged at the mRNA level (Figure S3A),
following NPR1 downregulation. Interestingly, NRP1 downregulation significantly increased the expression
of mitochondria-specific iron importer Mitoferrin-1 but had no effect on Mitoferrin-2 expression (Fig-
ure S3C). Taken together these data suggest that loss of NRP1 induces iron accumulation by dysregulating
iron influx-efflux balance in ECs.
To investigate whether iron accumulation reduces mitochondria activity in HDMECs downregulated for
NRP1 expression, we measured the mitochondrial membrane potential DJ in HDMECs expressing or
lacking NRP1 and treated with the iron chelator deferoxamine (Figure 4F). As previously shown (Figures
2A–2D), NRP1 downregulation significantly decreased the DJ-dependent TMRM staining (Figures 4F
and 4G). Strikingly, deferoxamine treatment of HDMECs si-NRP1 rescued the TMRM staining to a level
comparable to HDMECs si-control (Figures 4F and 4G), indicating that iron-mediated ROS production
causes mitochondrial damage, which results in reduced DJ. Similarly, deferoxamine treatment rescued
DJ in HUVECs lacking NRP1 (Figures S3D and S3E). Thus we investigated whether iron induces ROS pro-
duction by measuring mitochondrial ROS in HDMECs si-NRP1 treated with the iron chelator deferox-
amine. As previously shown (Figures 2E and 2F), MitoSOX live-stained HDMECs lacking NRP1 expression
have significantly higher mitochondrial superoxide level compared with control cells (Figures 4H and 4I).
Importantly, deferoxamine treatment normalized superoxide levels in HDMECs si-NRP1 to levels similar
to control cells (Figures 4H and 4I). Taken together these data demonstrate that lack of NRP1 induces
iron-dependent oxidative stress, which causes a decrease of the mitochondrial activity and increases
mitochondrial ROS levels.
NRP1 Regulates Iron Homeostasis via ABCB8
To further investigate whether NRP1 regulates iron-dependent oxidative stress via ABCB8, we downregu-
lated ABCB8 expression using siRNA in HDMECs (si-ABCB8). ABCB8 mRNA, immunostaining, and immu-
noblotting analyses showed that HDMECs transfected with si-ABCB8 had significantly reduced ABCB8
expression (Figures 5A–5C and S3F). Then we investigated whether ABCB8 downregulation decreases
mitochondrial DJ similarly to NRP1 knockdown and whether deferoxamine treatment could normalize
DJ in HDMECs and HUVECs knockdown for ABCB8. HDMECs and HUVECs lacking ABCB8 expression
showed reduced TMRM staining compared with control (Figures 5D, 5E, S3G, and S3H) similarly to
NRP1 downregulation (Figures 2B–2D, 4F, and 4G). Strikingly, deferoxamine treatment restored DJ of
HDMECs and HUVECs si-ABCB8 to levels comparable with those of control cells (Figures 5D, 5E, S3G,
and S3H). These data indicate that lack of ABCB8 or NRP1 similarly induces an iron-mediated decrease
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Figure 4. NRP1 Regulates Iron Homeostasis And Iron-Dependent Oxidative Stress
(A) Intracellular total iron (Fe2+ plus Fe3+) of HDMECs si-control or si-NRP1 expressed as percentage relative to si-control (mean G SEM; n = 3).
(B) HDMECs si-NRP1 or si-control were incubated with 5 mM Mito-FerroGreen (gray) and 300 nM MitoTracker Deep Red FM (red); scale bar, 20 mm.
(C) Mito-FerroGreen fluorescent signal per cell was quantified and expressed as percentage relative to si-control (mean G SEM; n = 3).
(D) HDEMCs si-NRP1 or si-control were stained for ferroportin-1 (green or gray) and counterstained with DAPI (blue); scale bar: 20 mm.
(E) Integrated density of ferroportin-1 was normalized to DAPI and expressed as fold change of si-control (mean G SEM; n = 4).
(F) HDMECs treated with deferoxamine 100 mM for 24 hr after 48 hr from transfection with si-NRP1 or si-control were incubated with 100 nM TMRM (gray);
scale bars, 20 mm.
(G) Integrated density of the TMRM signal normalized to cell number determined by manual counting using high-contrast images (panel F, green images)
and expressed as percentage relative to si-control (mean G SEM; n = 4).
(H) HDMECs si-control or siNRP1 untreated or treated with deferoxamine 100 mM for 24 hr were incubated with 5 mM MitoSOX (red), counterstained with
Hoescht 33342 (blue); scale bar: 20 mm.
(I) Integrated density of the MitoSOX signal expressed as percentage relative to untreated si-control (mean G SEM; n = 4).
*p < 0.05, ***p < 0.001; Student’s t test. See also Figure S3.
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Figure 5. NRP1 Regulates Iron-Dependent Oxidative Stress via ABCB8
(A) Quantification of ABCB8mRNA by RT-qPCR in HDMECs si-ABCB8, si-NRP1, or si-control. Transcripts levels were expressed as fold change of si-control
(mean G SEM; n = 3).
(B) Immunostaining for ABCB8 (green) in HDMECs si-ABCB8 or si-control counterstained with DAPI (blue); scale bar, 20 mm.
(C) ABCB8 integrated density in optical z stacks was normalized to DAPI integrated density and expressed as percentage relative to si-control (meanG SEM;
n = 3).
(D) HDMECs treated with deferoxamine 100 mM for 24 hr, 48 hr after transfection with si-ABCB8 or si-control were incubated with 100 nM TMRM (gray); scale
bar, 20 mm.
(E) Integrated density of the TMRM signal was normalized to cell number determined by manual counting using high-contrast images (Figure 5D, green
panels) and expressed as percentage (mean G SEM; n = 4).
(F) HDMECs si-ABCB8 or si-control were incubated with 5 mM MitoSOX (red) and counterstained with Hoescht 33342 (blue); n = 4; scale bar, 20 mm.
(G) Integrated density of the MitoSOX signal was quantified as percentage of si-control (mean G SEM; n = 4).
(H) Quantification of NRP1 and ABCB8 mRNA by RT-qPCR in HDMECs single or double transfected with si-NRP1 and si-ABCB8 or si-control (meanG SEM;
n = 3).
(I) HDMECs single or double transfected with si-ABCB8 and si-NRP1 or si-control were incubated with 100 nM TMRM (gray); scale bar, 20 mm.
(J) Integrated density of the TMRM signal was normalized to cell number determined by manual counting using high-contrast images (panel I, green images)
and expressed as percentage (mean G SEM; n = 3).
*p < 0.05, ***p < 0.001; n.s., not significant; Student’s t test. See also Figure S3.
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Because ABCB8 downregulation induces iron-mediated ROS production in cardiomyocytes and mela-
noma cells (Ichikawa et al., 2012, 2014), we investigated whether ABCB8 regulates iron-dependent oxida-
tive stress by measuring mitochondrial superoxide level in HDMECs expressing or lacking ABCB8 and
treated with deferoxamine. MitoSOX live-staining analysis showed that ABCB8-deficient HDMECs had
significantly higher MitoSOX staining compared with si-control (Figures 5F and 5G), similarly to NRP1
downregulation (Figures 2E and 2F), suggesting that both NRP1 and ABCB8 regulate iron-mediated
ROS production in ECs. Accordingly, deferoxamine completely inhibited superoxide production in
HDMECs si-ABCB8 (Figures 5F and 5G). These data demonstrate that ABCB8 downregulation induces
iron-dependent ROS production in ECs and suggest that NRP1 regulates these processes through
ABCB8.
To further investigate this hypothesis, we measured mitochondrial DJ and ROS in HDMECs with a simul-
taneous knockdown for ABCB8 and NRP1. Downregulation of both NRP1 and ABCB8 (Figure 5H) had no
additive effect in inhibiting mitochondrial DJ compared with HDEMCs lacking NRP1 or ABCB8 only (Fig-
ures 5I and 5J), suggesting that NRP1 and ABCB8 act on the same cellular pathway.NRP1 and ABCB8 Loss Induces Iron-Dependent Premature Senescence in ECs
Cellular senescence can be prematurely induced by telomere-independent mechanisms, which include
excessive oxidative stress and mitochondrial dysfunction (Erusalimsky, 2009). Thus we hypothesized that
loss of NRP1 could result in premature senescence in ECs, and we investigated whether NRP1-deficient
ECs presented the hallmarks of senescence. Cellular senescence is characterized by elevated senes-
cence-associated b-galactosidase (SA-b-gal) activity (Dimri et al., 1995; Ota et al., 2008; Warboys et al.,
2014), increased p16 levels (Chen et al., 2006; Song et al., 2008), reduction of SIRT1 expression (Ota
et al., 2008), and reduced proliferation. NRP1-deficient HDMECs showed an increased number of SA-
b-gal-positive cells compared with control (Figures 6A and 6B) alongside increased p16 levels and reduced
SIRT1 expression (Figures 6C–6E). Furthermore, cell counting analysis showed a reduced cell growth rate of
NPR1-downregulated HDMECs compared with control under normal growth conditions (Figure 6F).
Because it has been previously reported that NRP1 is required to mediate anti-apoptotic signals in
serum-starved ECs (Wang et al., 2007), we measured the apoptosis marker annexin-V (Koopman et al.,
1994) by fluorescence-activated cell sorting (FACS) to determine whether the reduced cell growth
observed in NRP1-deficient ECs was due to increased apoptosis also in normal growth conditions. The
number of cells undergoing apoptosis was similar in HDMECs si-NRP1 and si-control (Figure 6G), suggest-
ing that the reduced cell growth observed in normal growth conditions is not caused by increased
apoptosis. Importantly, FACS analysis of bromodeoxyuridine-labeled HDMECs si-NRP1 or si-control
showed that NRP1 deficiency significantly reduced the number of proliferating cells in HDMECs si-NRP1
compared with controls (Figure 6H). Thus NRP1 loss reduces EC proliferation without inducing apoptosis
in normal growth conditions.
Because EC proliferation was affected by NRP1 loss, we investigated whether the expression of cyclins was
affected byNRP1 knockdown. In agreement with the reduced cell growth, immunoblotting analysis showed
reduced cyclin D1 and cyclin B1 levels and a concomitant increase in cyclin D2 expression in HDMECs si-
NRP1 compared with si-control (Figures 6I and 6J). Thus loss of NRP1 affects cyclin expression and there-
fore cell cycle progression in ECs.
To further investigate the role of NRP1 in EC senescence, wemeasured p16 protein level and the number of
SA-b-gal-positive cells also in primary mouse lung endothelial cells (MLECs) isolated frommice genetically
deficient for NRP1 in ECs (Nrp1ECKO) and from control littermates (Nrp1WT). Nrp1ECKO MLECs showed
significantly higher p16 protein expression (Figures 6K and 6L) and increased number of SA-b-gal-positive
cells (Figures 6M and 6N) compared with MLECs isolated from Nrp1WT littermates. Taken together these
data demonstrate that loss of NRP1 induces premature senescence.
We then investigated whether by regulating iron homeostasis the NRP1-ABCB8 pathway protects ECs from
premature senescence. SA-b-gal staining showed that NRP1 or ABCB8 downregulation similarly increased
the number of SA-b-gal-positive HDMECs (Figures 6O and 6P). Furthermore, treatment of HDMECs lacking
both NRP1 and ABCB8 with deferoxamine reduced SA-b-gal-positive cells to a level similar to untreated si-
control (Figures 6O and 6P). These data show that NRP1-ABCB8 pathway suppresses iron-induced ECs
senescence.216 iScience 11, 205–223, January 25, 2019
Figure 6. NRP1 Suppresses Iron-Dependent Premature Senescence via ABCB8
(A) SA-b-gal staining in HDMECs si-control or si-NRP1 72 and 120 hr after transfection.
(B) Quantification of SA-b-gal-positive cells (mean G SEM; n = 3).
(C) Representative immunoblots for NRP1, p16, and SIRT1 of HDMECs si-control or si-NRP1.
(D) Quantification of p16 expression level as pixel intensity relative to GAPDH pixel intensity (mean G SEM; n = 4).
(E) Immunofluorescence for NRP1 (green) and p16 (red) together with DAPI staining; scale bar, 20 mm; n = 2.
(F) Cell counting assay at 72 and 120 hr after transfection in HDMECs si-control or si-NRP1 (mean G SEM; n = 3).
(G) FACS analysis of annexin-V-positive cells in HDMECs si-control or si-NRP1 (mean G SEM; n = 3).
(H) Analysis of bromodeoxyuridine (BrdU)-positive cells in HDMECs si-NRP1 or si-control (mean G SEM; n = 3).
(I) Representative immunoblotting for cyclin D1, cyclin B1, cyclin D2, and CHD5 with GAPDH serving as a loading control of HDMECs si-control or si-NRP1.
(J) Quantification of the indicated protein expression levels as pixel intensity relative to GAPDH pixel intensity (mean G SEM; n = 4).
(K) Representative immunoblotting for the indicated proteins of MLECs from Nrp1ECKO and Nrp1WT littermates.
(L) Quantification of p16 total levels as pixel intensity relative to GAPDH (mean G SEM; n = 4).
(M) SA-b-gal assay of MLECs from Nrp1ECKO and Nrp1WT littermates.
(N) Quantification of SA-b-gal-stained MLECs after four and eight tissue culture passages.
(O) SA-b-gal staining in HDMECs double transfected for 24 hr with si-NRP1, si-ABCB8, or si-control and treated with deferoxamine 100 mM for 48 hr.
(P) Quantification of SA-b-gal-positive cells (mean G SEM; n = 3).
*p < 0.05, ***p < 0.001; n.s., not significant; Student’s t test.
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Figure 7. Schematic Representation of the NRP1-ABCB8 Pathway in Regulating Iron Homeostasis, Iron-
Dependent Oxidative Stress, and Cellular SenescenceDISCUSSION
Despite oxygen availability, ECs mainly rely on anaerobic glycolysis to meet their energy demand and to
produce ATP (De Bock et al., 2013). Thus although mitochondria provide a limited contribution to energy
production in ECs, they are essential for EC function, because altering mitochondrial dynamics contributes
to endothelial dysfunction (Shenouda et al., 2011). Accordingly, ECs lacking MFN1 show reduced VEGF-
induced angiogenesis and inhibited AKT-dependent activation of endothelial nitric oxide synthase (Lugus
et al., 2011). Here we show that NRP1 regulates mitochondrial activity and dynamics. ECs lacking NRP1 fail
to form the complex mitochondrial network observed in control ECs and show a reduced level of MFN1.
Mitochondrial dysfunction plays a role in the onset of cellular senescence, and preventing mitochondrial
dysfunction delays replicative senescence in human primary cells (Passos et al., 2007). Furthermore, exces-
sive production of ROS is associated with mitochondrial dysfunction and with the induction of p16INK4A-
dependent senescence (Davalli et al., 2016).
Cellular senescence limits the capacity of tissues to undergo repair by cell proliferation and thereby accel-
erates age-related degenerative diseases such as sarcopenia (Kudryashova et al., 2012), osteoarthritis
(Price et al., 2002), pulmonary fibrosis (Tsuji et al., 2010), and Alzheimer disease (Bhat et al., 2012). In the
aging vasculature, senescent ECs accumulate in atherosclerotic lesions and likely contribute to disease
progression by creating a pro-inflammatory and pro-thrombotic environment (Minamino et al., 2002; Vasile
et al., 2001; Warboys et al., 2014). Here we show that ECs lacking NRP1 show the hallmarks of cellular senes-
cence, including high levels of p16 and decreased SIRT1 expression alongside deregulated cyclin expres-
sion, reduced proliferation, as well as an increased SA-b-gal staining.
Furthermore, we show that NRP1 prevents mitochondrial superoxide production and EC senescence by
promoting iron homeostasis via the mitochondrial transporter ABCB8 (Figure 7). As a pool of NRP1 local-
izes in the mitochondria and interacts with the mitochondrial inner membrane transporter ABCB8, the
NRP1-ABCB8 complex likely forms in the inner mitochondrial membrane compartment. NRP1 downregu-
lation reduces ABCB8 protein expression and phosphorylation. The ABCB8 reduction observed in NRP1-
deficient ECs could be explained on one hand by the reducedmitochondria content, and on the other hand
by the disruption of the ABCB8/NRP1 complex, which could promote localization of ABCB8 in the mito-
chondria or prevent ABCB8 protein degradation. Importantly, because HDMECs si-NRP1 show a partial
reduction in ABCB8 protein content but PTMscan and PLA analyses display an almost complete inhibition
in ABCB8 phosphorylation, our data suggest that the decreased phosphorylation of ABCB8 observed in
HDMECs si-NRP1 could be caused by a combination of the reduced ABCB8 protein level with an additional
mechanism that could inhibit ABCB8 phosphorylation in NRP1-deficient ECs.218 iScience 11, 205–223, January 25, 2019
Treatment with the iron chelator compound deferoxamine restores the mitochondrial membrane potential
of NRP1-deficient HDMECs and HUVECs and abrogates mitochondrial superoxide production. Deferox-
amine has been shown to promote blood flow recovery in a hindlimb ischemia mouse model (Ikeda
et al., 2011) and to increase hypoxia-inducible transcription factor 1, VEGFA, and COX-2 levels in ischemic
skeletal muscle and in macrophages (Asikainen et al., 2005; Woo et al., 2006). A role for iron has also been
proposed in the pathogenesis of atherosclerosis (Kiechl et al., 1997; Lee et al., 1999), and deferoxamine
treatment improved nitric oxide-mediated, endothelium-dependent vasodilation in patients with coronary
artery disease (Duffy et al., 2001).
By showing that deferoxamine restores mitochondrial membrane potential and reduces ECs senescence in
NRP1-deficient ECs (Figure 7), our data raise the possibility that targeting iron metabolism could be a
promising strategy to prevent ECs senescence and preserve endothelial function.
The function of NRP1 in regulating mitochondrial homeostasis and iron metabolism independently of
VEGFR2 signaling expands the current model, which suggests that NRP1 promotes several signals in
ECs and is not acting exclusively as a VEGF co-receptor (Aspalter et al., 2015; Hu et al., 2007; Raimondi
et al., 2014, 2015, 2016). Because the NRP1-ABCB8 pathway is essential to prevent iron-induced mitochon-
drial dysfunction, our data suggest that in addition to its well-characterized role in angiogenesis, arterio-
genesis (Fantin et al., 2014; Kawasaki et al., 1999; Lanahan et al., 2013; Raimondi, 2014), and vascular perme-
ability (Fantin et al., 2017; Roth et al., 2016), NRP1 regulates a fundamental pathway that promotes ECs
homeostasis.
In ECs, mitochondria function as a metabolic hub (Davidson, 2010; De Bock et al., 2013; Quintero et al.,
2006). Mitochondria are involved in the production of aspartate and glutamate needed for deoxynucleo-
tide synthesis (Rohlenova et al., 2017; Schoors et al., 2015), in the regulation of glutamine metabolism
whose inhibition causes vessel-sprouting defects due to impaired proliferation and migration (Huang
et al., 2017), and in iron metabolism. Because Fe/S clusters and heme’s precursor biosynthesis occurs in
the mitochondria, physiological mitochondrial iron levels are maintained through the activity of mitochon-
dria-specific iron importers and exporters. Mitoferrin-1 and mitoferrin-2 mediate iron uptake in fibroblasts,
murine embryonic stem cells, and erythroleukemia cells (Chen et al., 2010; Paradkar et al., 2009), whereas
recent evidence shows that the mitochondrial inner membrane transporter ABCB8 regulates ionic iron
export and protects mitochondria from iron overload in melanoma cells and cardiomyocytes (Ardehali
et al., 2005; Ichikawa et al., 2012, 2014). Accordingly, mouse mutants lacking ABCB8 expression in cardio-
myocytes develop cardiomyopathy due to increased mitochondrial iron, which results in iron-dependent
ROS production and mitochondrial dysfunction (Ichikawa et al., 2012). Our data show that ABCB8 plays
a key role in iron homeostasis also in ECs. Furthermore, our data suggest a profound role of NRP1 in regu-
lating mitochondrial iron because its downregulation simultaneously increases the mitochondrial importer
mitoferrin-1 transcript and decreases ABCB8 protein level. As the data presented here and in previous re-
ports (Ichikawa et al., 2012, 2014) show that ABCB8 prevents iron-mediated mitochondrial damage, it is
possible that by decreasing ABCB8-dependent iron export, NRP1 loss impairs mitochondrial function
and therefore iron metabolism, thus triggering a compensatory response to increase transcription of the
mitochondrial iron importer mitoferrin-1 to restore iron metabolism and of ferroportin-1 to maintain phys-
iological intracellular iron levels.
Our data suggest that promoting NRP1-dependent signaling could be particularly relevant in age-
related diseases characterized by increased oxidative stress or by deregulation of iron metabolism
such as atherosclerosis, vascular dementia, and Alzheimer disease. Oxidative stress and iron-mediated
free radical production mediate neuronal death and gliosis. Furthermore, oxidative stress induces endo-
thelial dysfunction in a model of cerebral ischemia (Jin et al., 2008). Importantly, patients with Alzheimer
or Parkinson diseases have higher iron content, which correlates with increased ROS levels in areas of the
brain prone to neurodegeneration (Manoharan et al., 2016). Recent evidence suggests that the neurode-
generative process observed in neurodegenerative diseases is initiated by blood-brain barrier dysfunc-
tion, caused by aging and cardiovascular conditions, resulting in increased oxidative stress, dysregula-
tion of nitric oxide, inflammation, and altered paracellular permeability (Oakley and Tharakan, 2014;
Sweeney et al., 2018). Whether NRP1 expression or activity is modulated in these diseases is unknown,
and our work suggests that pathological downregulation of NRP1 could have detrimental consequences
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In conclusion, our data demonstrate an unexpected function of NRP1, which acts as a key regulator of mito-
chondria and iron homeostasis in ECs by suppressing iron accumulation and iron-dependent oxidative
stress via ABCB8, independently of VEGF signaling. Our work suggests that the NRP1-ABCB8 pathway
could protect ECs function from iron-dependent ROS-induced endothelial dysfunction and have a protec-
tive role in age-related diseases.
Limitation of the Study
To identify the NRP1-ABCB8 pathway and to investigate its role in ECs, we used an in vitro approach that
relied on siRNA-mediated transient downregulation of NRP1 and ABCB8. This approach allows neither the
long-term effects of NRP1 or ABCB8 downregulation in ECs nor the role of the NRP1/ABCB8 pathway in
endothelial function in vivo to be studied. Although we have established that genetic manipulation of
NRP1 expression prevents oxidative stress in a zebrafish model and protects ECs from senescence in an
ex vivo model, whether the NRP1-ABCB8 pathway plays a role in physiological or pathological angiogen-
esis, or in homeostatic EC functions such as nitric oxide synthase activation, vascular permeability, and
leukocyte-EC adhesion remains to be addressed. Furthermore, the mechanisms that modulate NRP1
expression in pathological contexts, such as neurodegenerative disorders or ischemia, are currently un-
clear and would need to be further investigated.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Transparent Methods, three figures, and one table and can be found
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Transparent Methods 
Cell culture and transfection:   
Human microvascular dermal ECs (HDMECs) were cultured in MV2 media 
with supplements (Promocell, UK). HUVECs were cultured in EGM-2 (Promocell, 
Germany). Primary MLECs were isolated from mice between 1 and 2 months of age 
by magnetic-activated cell sorting (MACS) with PECAM (BD, UK) and ICAM2 (BD, 
UK). MLECs were cultured on 10 µg/ml FN in DMEM-GlutaMAX supplemented with 
20% FBS, nonessential amino acids (Life Technologies, UK), and ECGS (Sigma-
Aldrich, UK). HDEMCs and HUVECs were cultured for up to five passages and 
transfected with Lipofectamine RNAiMAX transfecting agent (Thermofisher, UK). 
The following siRNAs were used to transfect HDMECs and HUVECs: SMARTpool 
siRNA targeting NRP1 (Dharmacon, USA; cat#: L-019484-00-0020); sequence 1: 
CGAUAAAUGUGGCGAUACU; antisense: AGUAUCGCCACAUUUAUCG; 
sequence 2: GGACAGAGACUGCAAGUAU; antisense: 
AUACUUGCAGUCUCUGUCC; sequence 3: GUAUACGGUUGCAAGAUAA 
Antisense: UUAUCUUGCAACCGUAUAC; sequence 4: 
AAGACUGGAUCACCAUAAA antisense: UUUAUGGUGAUCCAGUCUU;  
SMARTpool siRNA targeting VEGFR2 (Dharmacon, USA; cat# L-003148-00-0010);   
sequence 1: GGGCAUGUACUGACGAUUA Antisense: 
UAAUCGUCAGUACAUGCCC; sequence 2: CUACAUUGUUCUUCCGAUA 
Antisense: UAUCGGAAGAACAAUGUAG; sequence 3: 
GCGAUGGCCUCUUCUGUAA; Antisense: UUACAGAAGAGGCCAUCGC 
sequence 4: GGAAAUCUCUUGCAAGCUA; Antisense: 
UAGCUUGCAAGAGAUUUCC; SMARTpool siRNA targeting ABCB8 (Dharmacon, 
USA; cat#: L-007306-02-0010;  Sequence 1: CAACACGGUCGUCGGUGAA; 
antisense: UUCACCGACGACCGUGUUG; sequence 2: 
UCACCUUCUUUGACGCCAA; Antisense: UUGGCGUCAAAGAAGGUGA: 
sequence 3: AACGGGAAGAGGAGCGCUA Antisense: 
UAGCGCUCCUCUUCCCGUU; sequence 4: GCAUUGUCGUCAUGGCCGA; 
antisense: UCGGCCAUGACGACAAUGC; Silencer® negative control siRNA (Life 
Technology, UK; cat# AM4635). In some experiments, HDMECs were transfected 
with Hs NRP1 7 FlexiTube siRNA single sequence (Cat. SI02663213) or Hs NRP1 
8 FlexiTube siRNA (Cat. SI02663213) from Qiagen, UK. In some experiments, cells 
were double transfected with both siNRP1 and siABCB8. The amount of siRNA was 
 maintained identical among the different single and double transfections. In some 
experiments, ECs were treated with mitoTEMPO 10µM (Sigma Aldrich, UK) or 
Deferoxamine (100 µM) (Sigma Aldrich, UK) for 24 hours in growth media. 
  
Animals:  
All animal procedures were performed in accordance with institutional and UK 
Home Office guidelines. Lung endothelial cells were isolated from C57/Bl6 wild type 
mice (Charles River Laboratories, UK), and mice carrying two floxed conditional null 
Nrp1 alleles (Nrp1fl/fl) combined with Pdgfb-iCreERT2-Egfp with codon-improved Cre 
on a C57/Bl6 background (Gu et al., 2003; Raimondi et al., 2014). Aortas were 
isolated from B6.129 (SJL)-Nrp1tm2Ddg/J(Gu et al., 2003) (Charles River Laboratories, 
UK) combined with C57/Bl6 Cdh5(PAC)-iCreERT2 with codon-improved Cre (Wang et 
al., 2010). Zebrafish lines Tg(fli1a:egfp)y5 (Lawson and Weinstein, 2002) and nrp1a 
sa1485 (generated by the Sanger Centre Zebrafish Mutation Project) were 
maintained and bred according to standard procedures (Westerfield, 1995). Ethical 
approval for zebrafish experiments was obtained from the Home Office UK under the 
Animal Scientific Procedures Act 1986. 
For tamoxifen-induction of CRE-mediated recombination, 0.5 mg of tamoxifen 
(Sigma Aldrich, UK) dissolved in peanut oil to 2 mg/ml was administered via 
intraperitoneal injection at the indicated times to generate Nrp1ECKO and Nrp1WT mice. 
 
Gene expression: 
mRNA was collected using the RNAeasy system (Qiagen, UK) and cDNA was 
prepared using Superscript III reverse transcription (Life Technology, UK) and 
amplified with SYBR Green PCR reagent (Quantabio, USA) and the following 
oligonucleotide primers:  
NRP1, 5′-GAAAAATCGAATGCTGAT-3′ and 5′-AATCCGGGGGACTTTATCAC-3′; 
VEGFR2, 5′-AGATGGTGTAACCCGGAGTG-3′ and 5′-
ACATGTCAGCGTTTGAGTGG-3′; ABCB8, 5’-AGTACTCTGATGGCTACCGC-3’ 
and 5’-CAGAGGTGGGGATGCTTACT-3’; HO-1, 5′-TTCTATCACCCTCTGCCT-3 
and 5′-CCTCTTCACCTTCCCCAACA-3’; SOD1, 5’-
GGATGAAGAGAGGCATGTTGGAGAC-3’ and  5’-
GTCTTTGTACTTTCTTCATTTCCACC-3’; SOD2, 5’-
AGCAGTGGAATAAGGCCTGT-3’ and 5’-CAAAGGGGAGTTGCTGGAAG-3’; 
 TRF1, 5’-CAGTTGGAGTGCTGGAGACT-3’ and 5’-AGCGTATACAACAGTGGGCT-
3’; Ferroportin-1,  5’-TACTTGTGCCTCCCAGATGG-3’ and 5’-
ATGGAACCACTCAGTCCCTG-3’; Mitoferrin-1, 5’-CCAGATCCCAAAGCCCAGTA-
3’ and 5’-CCATACTCCCAGCTATCCCG-3’; Mitoferrin-2, 5’-
CCACGCCCTTTATTTTGCCT-3’ and 5’-TCCTCTGCTTGACCACTTCC-3’; GAPDH, 
5’-CAAGGTCATCCATGACAACTTTG-3’ and 5’-GGGCCATCCACAGTCTTCTG-3’ 
 
Immunoblotting:  
Cells were lysed in 150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 50mM 
Glycerophosphate (Sigma-Aldrich, UK), 1% Tween-20, 0.2% Igepal (Sigma-Aldrich, 
UK) in the presence of protease inhibitor cocktail 2 (Sigma-Aldrich, UK) and 
phosphatase inhibitor cocktail (Sigma-Aldrich, UK). 35µg of protein lysate were 
resuspended in Laemmli buffer, denatured for 5 minutes at 95˚C, separated by SDS-
PAGE and transferred to nitrocellulose membrane (Whatman, USA). Nitrocellulose 
membranes were immunoblotted with the following primary antibodies: mouse anti-
GAPDH (Abcam, UK); rabbit anti-NRP1, rabbit anti-VEGFR2 (Cell Signaling 
Technology, USA); rabbit anti-TOM20, rabbit anti-MFN1, rabbit anti-MFN2 
(Proteintech, USA), mouse monoclonal anti-KDEL (BD, UK), mouse anti-EEA1 (BD, 
UK), rabbit anti-ABCB8 (Sigma Aldrich, UK), mouse anti-Transferrin-1 (HTF-14) 
(Novus Biologicals, UK), goat anti-CDH5, rabbit anti-human p16 (C-20) and rabbit 
anti-mouse p16 (M-156) (Santa Cruz Biotechnology, USA); rabbit anti-SIRT1, rabbit 
anti-cyclin D1, rabbit anti-cyclin D2, (Cell Signaling Technology, USA). HRP-
conjugated secondary antibodies were used for chemiluminescence detection with 
ECL prime (Amersham, UK) and protein levels were quantified by densitometry with 
ImageJ (NIH, Bethesda US). 
 
Immunoprecipitation: 
ECs were lysed in 50 mM Tris, pH 8.0, 50 mM KCl, 1% (vol/vol) NP-40 in the 
presence of protease inhibitor cocktail 2 and phosphatase inhibitor cocktail. 1mg of 
protein was incubated with 3µg goat anti-NRP1 (Raimondi et al., 2014), or control 
goat or rabbit IgG (Santa Cruz Biotechnology) and then with 30 µl protein G 
Sepharose 4 fast flow (GE Healthcare, UK) at 4°C. Beads were washed three times 
with lysis buffer on a rotating wheel at 4°C for 5 minutes and resuspended in 50µl 
Laemmli sample buffer for SDS-PAGE and immunoblotting. 
  
Mitochondrial Fractionation:  
Mitochondrial fractionation was performed using the Qproteome Mitochondria 
Isolation Kit (Qiagen, UK). Briefly, 12 million of HDMECs were suspended in Lysis 
Buffer, centrifuged and the resulting pellet was resuspended in Disruption Buffer. The 
pellet was disrupted by repeatedly passing through a 23G blunt ended needle to 
ensure complete cell disruption and recentrifuged to pellet nuclei, cell debris, and 
unbroken cells. Then, the supernatant containing mitochondria and the microsomal 
fraction was centrifuged to pellet mitochondria. Mitochondria were washed and 
resuspended in Mitochondria Storage Buffer and carefully pipetted on top of layers of 
a gradient purification buffer which allowed the mitochondria to form a band. The band 
was removed, and the high-purity mitochondria lysed and analysed by 
immunoblotting for NRP1, GAPDH, ABCB8, TOM20, KDEL and EEA1. Mouse 
monoclonal [10C3] anti-KDEL (BD, UK) and mouse monoclonal clone 14 anti-EEA1 
(BD, UK) were used for immunoblotting analysis. 
 
Immunofluorescence:  
For experiments with fixed samples, HDMECs were fixed in 4% formaldehyde 
in PBS for 10 minutes, permeabilised in 0.25% Triton X-100 in PBS for 3 minutes, 
blocked for 30 minutes in 0.1%BSA in PBS and incubated overnight with the following 
primary antibodies: Rabbit anti-TOM20, (Proteintech, UK), rabbit anti-ABCB8 (Sigma, 
UK), mouse anti-NRP1 (R&D Systems, UK), mouse anti-Transferrin-1 (Santa Cruz 
Biotechnology, US). The following conjugated secondary antibodies were used: 
Alexa-488 conjugated goat anti-rabbit/anti-mouse or Alexa-594 anti-rabbit/anti-
mouse secondary antibodies (ThermoFisher Scientific, UK) and DAPI (Sigma-
Aldrich, UK). Images were acquired with a plan apochromat 63X 1.4 NA oil objective 
on an LSM780 confocal microscope (Zeiss, Germany). Confocal z-stacks were 
acquired with an LSM780 laser scanning confocal microscopes (Zeiss, Germany). 
Maximal intensity projections were generated with ImageJ (NIH, Bethesda, USA) and 
normalized to DAPI pixel intensity. Mitochondrial areas and volumes per cell were 
calculated by generating a 3D-rendered surface based on Mitotracker staining with 
IMARIS (Bitplane, AG). For colocalization analysis, z-stacks acquired with an 
LSM780 laser scanning confocal microscopes (Zeiss) were deconvoluted with 
Huygens Deconvolution software (Scientific Volume Imaging B.V., The Netherlands) 
 and analysed for colocalization using the intensity correlation analysis plug-in for 
ImageJ (NIH, Bethesda, USA); 3D projection was generated and analysed with 
Volocity (PerkinElmer, UK). 
 
Whole-mount aorta: 
Aortas were obtained by dissection from Nrp1WT or Nrp1ECKO mice, fixed in 4% 
paraformaldehyde for 5 minutes, permeabilised with 1:1 Methanol:Acetone for 5 
minutes and blocked with 3% BSA in PBS-T for 1 hour. Samples were incubated 
overnight in 3% BSA in PBS-T with goat anti-NRP1 (R&D, UK) and rabbit anti-
PECAM (Invitrogen, UK) or with goat anti-ABCB8 (Santa Cruz Biotechnology, US) 
and rabbit anti-PECAM. Primary antibodies were detected with Alexa-488 or Alexa-
555 anti-rabbit/anti-goat secondary (ThermoFisher Scientific, UK). Nuclei were 
counterstained with DAPI. Z-projection were generated with ImageJ (NIH, Bethesda, 
USA) and z-stack pixel intensity was analysed with ImageJ (NIH, Bethesda, USA). 
 
Mitosox live-staining:  
ECs were incubated with 5µM Mitosox (Sigma-Aldrich, UK) and 5µg/ml 
Hoescht 33342 (Sigma-Aldrich, UK) in HBSS with Ca2+ and Mg2+ (Life Technology, 
UK) for 8 minutes, washed three times with HBSS with Ca2+ and Mg2+ before imaging 
with an LSM780 confocal microscope with a plan apochromat 63X 1.4 NA oil objective 
(Zeiss, Germany). In some cases, cells were treated with 100µM Deferoxamine 
(Sigma-Aldrich, UK) for 24 hours before imaging. Mitosox and Hoescht 33342 
integrated density was determined with ImageJ (NIH, Bethesda, USA).  
 
CellROX: 
Zebrafish embryos were raised at 28.50C in fish water and to prevent pigment 
formation, 0,003% phenylthiourea (PTU, Sigma) was added to the fish water at 10hpf. 
3dpf embryos were incubated in the dark with 2.5 μM CellROX (Invitrogen) in 10% 
DMSO for 45 minutes. Followed CellROX staining, embryos were anaesthetised with 
MS-222 (Sigma-Aldrich, UK), immobilised in 1.2% low melting point agarose (Sigma-
Aldrich, UK) and imaged from a lateral perspective using a Leica SP8 confocal 
microscope. During confocal analysis, we excluded territories containing pigment cells 
as, even after PTU treatment, showed autofluorescence that could not be 
 distinguished from CellROX labelling. CellROX staining in the vasculature was 
quantified with IMARIS (Bitplane, AG) by applying a virtual mask to the z-stacks 
acquired by high-resolution confocal microscopy to isolate GFP-positive vascular 
territories. Thus, cellROX signal within the vasculature was quantified and normalized 
to GFP signal.  
Tetramethylrhodamine methyl ester (TMRM) live-staining:  
ECs were incubated with 100nM TMRM for 30 minutes in growth MV2 media 
(HDMECs) or EGM2 (HUVECs), washed three times with HBSS with Ca2+ and Mg2+ 
before imaging with an LSM 510 confocal microscope with a plan apochromat 63X 
1.4 NA oil objective (Zeiss, Germany). In some cases, cells were nuclear 
counterstained using DRAQ5 (ThermoFisher, UK) or treated with 100µM 
Deferoxamine (Sigma-Aldrich, UK) for 24 hours before imaging. TMRM integrated 
density was determined with ImageJ (NIH, Bethesda, USA) and normalized to the 
number of cells. In some experiments, ECs were incubated with 100nM TMRM and 
300nM Mitotracker Deep Red to simultaneously visualise mitochondria and 
mitochondrial membrane potential and live-imaged  with an LSM 510 confocal 
microscope with a plan apochromat 63X 1.4 NA oil objective (Zeiss, Germany). 
TMRM and Mitotracker integrated density was determined with ImageJ (NIH, 
Bethesda, USA) and expressed as TMRM/Mitotracker ratio. 
 
Mitotracker staining:  
ECs were incubated with serum-free MV2 media (Promocell, Germany) 
containing 500nM MitoTracker™ Orange (ThermoFisher, UK) for 30 minutes. Cells 
were washed three times in HBSS Ca2+ and Mg2+ (Life Technology, UK), fixed in 4% 
PFA for 10 minutes at RT, nuclear counterstained with DAPI and imaged with an 
LSM710 confocal microscope with a plan apochromat 63X 1.4 NA oil objective (Zeiss, 
Germany).  
 
Mito-FerroGreen live-staining: 
ECs were washed three times with HBSS supplemented with Ca2+ and Mg2+ and 
incubated for 30 minutes with 5µM Mito-FerroGreen and 300nM Mitotracker Deep 
Red. Then, ECs were washed three times with HBSS supplemented with Ca2+ and 
Mg2+ and live-imaged with a widefield microscope with a plan apochromat 40X air 
 objective (Zeiss, Germany) or with an LSM780 confocal microscope with a plan 
apochromat 63X 1.4 NA oil objective (Zeiss, Germany). Mito-FerroGreen pixels were 
determined with ImageJ (NIH, Bethesda, USA) and normalized to the number of cells. 
 
Intracellular Iron assay: 
Intracellular iron of HDMEC transfected with si-control or si-NRP1 for 72 hours was 
measured using the colourimetric Iron Assay Kit (Catalog #K390-100 Biovision, US) 
following the manufacturer’s instructions. The kit measures Ferrous and Ferric ion in 
tissues or cell samples (Bai et al., 2017). In the assay, ferric carrier proteins will 
dissociate ferric iron into solution in the presence of acid buffer. After reduction to the 
ferrous form (Fe2+), iron reacts with Ferene-S to produce a stable coloured complex 
with absorbance at 593 nm.  
 
Proximity ligation assay: 
HDMECs were grown on gelatinised coverslips in 8-well chambers (Labtek, 
Sigma-Aldrich, UK). Cells were fixed with 4% paraformaldehyde for 15 minutes prior 
to blocking with 3% BSA for 1 h. PLA was performed following the manufacturer’s 
instructions (Duolink, Sigma-Aldrich, UK) using primary mouse anti-NRP1 (antibody 
R&D Systems, UK), goat anti-ABCB8 (Santa Cruz Biotechnology, USA), rabbit anti-
TOM20 (Proteintech, UK)  and mouse anti-phosphoserine antibody (clone PSR-45, 
P5747, Sigma-Aldrich, UK). As control isotype mouse IgG (Santa Cruz 
Biotechnology, USA) and goat IgG (Santa Cruz Biotechnology, USA) were 
respectively used in combination with goat anti-ABCB8 or mouse anti-NRP1 or rabbit 
anti-TOM20. Cells were mounted with Vectashield (Vector Laboratories, USA) and 
imaged with an LSM780 confocal microscope with a plan apochromat 63X 1.4 NA oil 
objective (Zeiss, Germany). PLA signal was analysed with the Analyze Particle 
function of ImageJ (NIH, Bethesda, USA).  
 
BrdU and apoptosis analysis by FACS:  
HDMECs were incubated with 10μM BrdU (Sigma) for 30 minutes, washed 
with PBS and harvested 48 hours after BrdU incorporation. Cells were then washed 
in PBS, trypsinized, pelleted and resuspended in ice-cold 70% ethanol for 30 minutes 
at 4°C. Fixed samples were then pelleted, resuspended in 2N HCl at room 
temperature for 30 minutes. Cells were washed in PBS supplemented with 0.1% BSA 
 and 0.2% Tween-20, pH 7.4, incubated with 2μl anti-BrdU (Becton Dickinson) at room 
temperature for 20 minutes, then washed in PBS-Tween and incubated with 
secondary antibody conjugated with Alexa (Molecular Probes) for 20 minutes at room 
temperature. Samples were washed in PBS, incubated with 50 μl RNAse (100 μg/ml, 
Sigma) at 37°C for 15 minutes and then incubated with Propidium iodide (50 μg/ml, 
Sigma). Apoptosis was assessed by flow cytometry by using annexin V and propidium 
iodide staining. Cells were washed in PBS, trypsinized, pelleted and resuspended in 
400 µl of binding buffer (Becton Dickinson, San Jose, CA); samples were incubated 
with 2 µl of annexin-V–FITC (Becton Dickinson) for 15 minutes at room temperature, 
then propidium iodide (5 µg/ml) was added to the sample. 
 
SA-β-gal assay:  
SA-β-gal activity was identified with the Senescence Cells Histochemical 
Staining Kit (catalogue number CS0030; Sigma-Aldrich, UK). Briefly, ECs were fixed 
for 6 minutes in 1X fixation buffer (2% formaldehyde, 0.2% glutaraldehyde, 7.0 mM 
Na2HPO4, 1.5 mM KH2PO4, 0.13 M NaCl, and 2.68 mM KCl), washed twice with 
PBS and then incubated for 16 hours at 37°C with SA-β-gal staining solution 
comprised of 5-bromo-4-chloro-3-indoyl β-D-galactopyranoside (X-Gal; 1mg/ml, 
diluted from a 40 mg/ml stock solution in N,N-dimethylformamide), potassium 
ferrocyanide (5 mM) and potassium ferricyanide (5 mM) in PBS (pH 6.0.) Following 
incubation, cells were washed three times with PBS and viewed under phase contrast 
using a Nikon Eclipse TS100 microscope with a 10x objective (N.A. 0.3, W.D. 16.0 
mm). Senescent ECs were identified by the presence of obvious blue reaction 
product. For each sample, the average percentage of SA-β-gal positive cells in each 
of three fields of view (0.785 mm2) was calculated as the value for that sample. 
 
PTMScan: 
Samples were analyzed using the PTMScan method as previously described 
(Stokes et al., 2012). Cellular extracts were prepared in urea lysis buffer, sonicated, 
centrifuged, reduced with DTT, and alkylated9 with iodoacetamide. Equal amounts of 
total protein for each sample was digested with trypsin and purified over C18 columns 
for enrichment with the Phosphotyrosine pY-1000 antibody (#8954) or Phospho-
Enrichment IMAC Fe-NTA Magnetic Beads (#20432). Enriched peptides were 
purified over C18 STAGE tips. Replicate injections of each sample were run non-
 sequentially on the instrument.  Peptides were eluted using a 90- or 150-minute linear 
gradient of acetonitrile in 0.125% formic acid delivered at 280 nL/min. Tandem mass 
spectra were collected in a data-dependent manner with an Orbitrap Velos or Elite 
Hybrid Ion Trap-Orbitrap Mass Spectrometer running XCalibur 2.0.7 SP1 using a top-
twenty MS/MS method, a dynamic repeat count of one, and a repeat duration of 30 
seconds.  Real-time recalibration of mass error was performed using lock mass with 
a singly charged polysiloxane ion m/z = 371.101237. MS/MS spectra were evaluated 
using SEQUEST and the GFY-Core platform. Files were searched against the NCBI 
homo sapiens FASTA database. A mass accuracy of +/-50 ppm was used for 
precursor ions and 1.0 Da for product ions. Enzyme specificity was limited to trypsin, 
with at least one tryptic (K- or R-containing) terminus required per peptide and up to 
four mis-cleavages allowed. Cysteine carboxamidomethylation was specified as a 
static modification, oxidation of methionine and phosphorylation on serine, threonine, 
or tyrosine residues were allowed as variable modifications. Reverse decoy 
databases were included for all searches to estimate false discovery rates and filtered 
using a 5% FDR in Core. Peptides were also manually filtered using a -/+ 5ppm mass 
error range and presence of at least one phosphorylated residue on each peptide.  
All quantitative results were generated using Progenesis V4.1 (Waters Corporation) 
to extract the integrated peak area of the corresponding peptide assignments. The 
accuracy of quantitative data was ensured by manual review in Progenesis or in the 
ion chromatogram files. A 2.5-fold cutoff was used to denote changes between 
samples and analytical % CV values were calculated for each peptide to determine 
reproducibility across runs. A limited version of the raw dataset containing only 
PTMscan data of mitochondria-associated proteins has been made available to 
readers due to intellectual property concerns. 
 
Statistical analyses: 
Statistical analyses were performed with GraphPad (Prism) or Office Excel 
(Microsoft); data obtained from cell lines were analysed with a two-tailed, paired t-
test; data obtained from the zebrafish experiments were analysed with a one-way 
ANOVA statistical test; data obtained from mouse experiments were analysed with a 
two-way ANOVA statistical test.  
 Supplemental Information Figures: 
Figure S1 related to Figure 1 and Figure 3 
 
  
Figure S1 – Related to Figure 1 and Figure 3: A) HDMECs si-control or si-NRP1 immunostained 
for NRP1, TOM20 and counterstained with DAPI (n=3). Arrows indicate NRP1 staining at the 
plasma membrane and in filopodia; Scale bars: 20µm.  B) Representative immunoblot for NRP1 
of HDMECs si-NRP1 or si-control 72 hours with GAPDH used as loading control; (n≥5). C) High 
magnification orthogonal view of NRP1 and TOM20 double-stained HDMEC showing 
colocalization (arrows) of NRP1 and TOM20 along X and Y axes; scale bars 3µm and 5µm. C’) 
High magnification of the area indicated in panel C, showing colocalization of TOM20 and NRP1 
within three-dimensional structures. D) Colocalization analysis of single z-planes extracted from 
the z-stack shown in panel C and in Figure 1A; Scale bar 15µm. E) PLA for TOM20 and NRP1 
or TOM20 and IgG isotype of HDMECs si-control and si-NRP1 analysed using a confocal 
microscope; Scale bars: 20µm. F) PLA signal (grey) per cells (mean ± SEM) was measured in 
a minimum of 92 cells from 2 independent experiments. G) Fractions isolated with Qproteome 
mitochondria isolation kit from HDMECs were immunoblotted for the indicated antibodies (n=3). 
H) Aortas of Nrp1fl/fl (Nrp1WT) injected daily with tamoxifen for 5 days and sacrificed after 1 month 
from injections stained with secondary only as negative control; bar 30µm. *, P < 0.05, Student’s 
t-test. 
 Figure S2, related to Figure 2 and Figure 3 
 
  
Figure S2 – Related to Figure 2 and Figure 3: A) HDMECs incubated with TMRM 100nM and 
counterstained with DRAQ5 (blue) were treated or left untreated with 10µM CCCP; n=2; Scale 
bars: 20µm. B) HUVECs siNRP1 or si-control were incubated with 100nM TMRM and 300nM 
Mitotracker Deep Red FM and live-imaged with a confocal microscope. C) TMRM and Mitotracker 
Deep Red FM integrated density was calculated, and the ratio visualised in the graph (mean ± 
SEM; n=4). D) Representative immunoblotting for NRP1 in lysates from HDMECs transfected with 
si-control, anti-NRP1 single sequence 7 or single sequence 8 siRNAs. GAPDH was used as 
loading control (n=3). E) HDMECs transfected with siNRP1 single sequence 7 or single sequence 
8 or si-control were incubated with 100nM TMRM and 300nM Mitotracker Deep Red FM and live-
imaged with a confocal microscope. F) TMRM and Mitotracker Deep Red FM integrated density 
was calculated, and the ratio visualised in the graph (mean ± SEM; n=3). G) Representative 
immunoblots for NRP1, HO-1 and GAPDH in HDMECs si-NRP1 or si-control. H) Quantification of 
expression levels as pixel intensity relative to GAPDH pixel intensity; n=3. I) Heat map showing 
data from PTMscan of phosphorylated mitochondrial proteins in HDMECs transfected with si-
control or si-NRP1 for 72 hours. Data are expressed as fold change of si-control; n=2. J) HDMECs 
were co-stained for ABCB8 (green) and TOM20 (red) with DAPI (blue) used as counterstaining. 
Right panels show a bi-parametric correlative histogram; Scale bars: 20µm. *, P < 0.05, Student’s 
t-test. 
 Figure S3, related to figure 4 and Figure 5 
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